Continuing Pharmacy Education / CE Master List / To Boost or Not to Boost: Exploring Blood Sugar Dilemmas-Recorded Webinar
Please use this button to register in our system as a new user, or to purchase a CE Activity.
For free CE's, returning users can simply click the "TAKE TEST/EVALUATION" button on the right.
Please use this button when you have completed the CE Activity and are ready to take the quiz and complete the evaluation.

To Boost or Not to Boost: Exploring Blood Sugar Dilemmas-Recorded Webinar

About this Course

This course is a recorded (home study version) of the CE Finale Encore Webinars.

 

Learning Objectives

Upon completion of this application based CE Activity, a pharmacist will be able to:

·       Define clinical inertia
·       Discuss the causes and consequences of clinical inertia in types 2 diabetes
·       Given a patient case, determine if you would boost or not boost treatment in a patient with type 2 diabetes
·       Identify the ways that pharmacists can reduce clinical inertia

Release and Expiration Dates

Released:  December 22, 2021
Expires:  December 17, 2024

Course Fee

$15 Pharmacist

ACPE UAN

0009-0000-21-056-H01-P

Session Code

21RW56-VXK92

Accreditation Hours

1.0 hours of CE

Additional Information

 

How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-21-056-H01-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

Stefanie Nigro, PharmD, BCACP, BC-ADM, CDCES
Associate Clinical Professor
University of Connecticut School of Pharmacy, Storrs, CT

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

  • Stefanie Nigro has no relationships with ineligible companies

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Content

POST TEST

1. According to the American Diabetes Association, how often should clinicians assess patients’ care plans to avoid inertia?
a. Monthly
b. Every 3-6 months
c. Annually

2. Which of the following statements is TRUE regarding clinical inertia in diabetes care?
a. Median time to treatment intensification for a patient with type 2 diabetes is often greater than 1 year
b. Primary care providers are more likely than clinical pharmacists to intensify treatment for patients with T2D
c. Clinical inertia is more likely to occur in patients with advanced T2D compared to newly diagnosed patients

3. Which of the following is a consequence of clinical inertia except?
a. Decreased risk of macrovascular complications
b. Increased health care spending
c. Quick resolutions of hyper or hypoglycemia

4. Which of the following pharmacist-led roles is most likely to reduce clinical inertia?
a. Dispensing antidiabetic drugs with review for potential interactions
b. Vaccinating patients with type 2 diabetes according to CDC guidelines
c. Participating in an interdisciplinary diabetes shared medical appointment

5. Which of the following drivers of inertia is correctly paired with its cause?
a. Denial of the disease; provider related
b. Fear of side effects; health-systems related
c. Medication regimen complexity; patient related

Handouts

Download

VIDEO